PDS Biotechnology Corp
PDSB1.095USD
+0.005+0.46%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
49.76MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über PDS Biotechnology Corp Unternehmen
PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.
Unternehmensinformationen
BörsenkürzelPDSB
Name des UnternehmensPDS Biotechnology Corp
IPO-datumOct 01, 2015
CEODr. Frank Bedu-Addo, Ph.D.
Anzahl der mitarbeiter24
WertpapierartOrdinary Share
GeschäftsjahresendeOct 01
Addresse303A College Road East
StadtPRINCETON
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl08540
Telefon18002083343
Websitehttps://www.pdsbiotech.com
BörsenkürzelPDSB
IPO-datumOct 01, 2015
CEODr. Frank Bedu-Addo, Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Frank Bedu-Addo, Ph.D.
Dr. Frank Bedu-Addo, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
690.87K
--
Mr. Stephen C. (Steve) Glover
Mr. Stephen C. (Steve) Glover
Independent Chairman of the Board
Independent Chairman of the Board
78.85K
--
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Independent Director
Independent Director
61.21K
--
Ms. Kamil Ali-Jackson, Esq., J.D.
Ms. Kamil Ali-Jackson, Esq., J.D.
Independent Director
Independent Director
11.76K
--
Dr. Ilian Petkov Iliev
Dr. Ilian Petkov Iliev
Director
Director
--
--
Mr. Mike Moyer
Mr. Mike Moyer
IR Contact Officer
IR Contact Officer
--
--
Mr. Spencer Brown
Mr. Spencer Brown
Senior Vice President, Compliance Officer, General Counsel, Corporate Secretary
Senior Vice President, Compliance Officer, General Counsel, Corporate Secretary
--
--
Mr. Stephan Toutain
Mr. Stephan Toutain
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Kirk V. Shepard, M.D.
Dr. Kirk V. Shepard, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Otis W. Brawley, M.D.
Dr. Otis W. Brawley, M.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Frank Bedu-Addo, Ph.D.
Dr. Frank Bedu-Addo, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
690.87K
--
Mr. Stephen C. (Steve) Glover
Mr. Stephen C. (Steve) Glover
Independent Chairman of the Board
Independent Chairman of the Board
78.85K
--
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Independent Director
Independent Director
61.21K
--
Ms. Kamil Ali-Jackson, Esq., J.D.
Ms. Kamil Ali-Jackson, Esq., J.D.
Independent Director
Independent Director
11.76K
--
Dr. Ilian Petkov Iliev
Dr. Ilian Petkov Iliev
Director
Director
--
--
Mr. Mike Moyer
Mr. Mike Moyer
IR Contact Officer
IR Contact Officer
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Jul 26
Aktualisiert: Sat, Jul 26
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Armistice Capital LLC
9.67%
The Vanguard Group, Inc.
3.30%
Bedu-Addo (Frank)
1.51%
BlackRock Institutional Trust Company, N.A.
1.05%
Sykes (Richard)
0.97%
Other
83.49%
Aktionäre
Aktionäre
Anteil
Armistice Capital LLC
9.67%
The Vanguard Group, Inc.
3.30%
Bedu-Addo (Frank)
1.51%
BlackRock Institutional Trust Company, N.A.
1.05%
Sykes (Richard)
0.97%
Other
83.49%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
9.80%
Investment Advisor
6.01%
Individual Investor
3.09%
Investment Advisor/Hedge Fund
1.54%
Research Firm
0.71%
Pension Fund
0.04%
Bank and Trust
0.01%
Other
78.80%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
187
9.67M
21.15%
+1.28M
2025Q1
201
9.77M
22.08%
+1.54M
2024Q4
205
5.67M
12.73%
-3.40M
2024Q3
205
5.76M
15.58%
-3.85M
2024Q2
208
6.94M
18.83%
-4.50M
2024Q1
195
8.96M
25.12%
-3.13M
2023Q4
194
9.68M
31.15%
-1.91M
2023Q3
192
9.20M
29.70%
-3.29M
2023Q2
183
9.26M
30.03%
-1.73M
2023Q1
149
11.76M
39.00%
-275.25K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Armistice Capital LLC
4.42M
9.67%
+4.42M
--
Mar 31, 2025
The Vanguard Group, Inc.
1.51M
3.3%
+4.41K
+0.29%
Mar 31, 2025
Bedu-Addo (Frank)
690.87K
1.51%
--
--
Apr 17, 2025
BlackRock Institutional Trust Company, N.A.
480.97K
1.05%
-4.48K
-0.92%
Mar 31, 2025
Sykes (Richard)
445.11K
0.97%
--
--
Apr 17, 2025
Geode Capital Management, L.L.C.
437.88K
0.96%
+20.66K
+4.95%
Mar 31, 2025
William Blair & Company, L.L.C. (Research)
257.20K
0.56%
+99.70K
+63.30%
Mar 31, 2025
UBS Financial Services, Inc.
245.33K
0.54%
+221.67K
+936.97%
Mar 31, 2025
State Street Global Advisors (US)
133.33K
0.29%
--
--
Mar 31, 2025
Conn (Gregory L Ph.D.)
123.59K
0.27%
--
--
Apr 17, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Micro-Cap ETF
0.01%
DFA Dimensional US Core Equity Market ETF
0%
Global X Russell 2000 ETF
0%
Avantis US Small Cap Equity ETF
0%
Proshares Ultra Russell 2000
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 Growth ETF
0%
iShares Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
Global X Russell 2000 Covered Call ETF
0%
Mehr Anzeigen
iShares Micro-Cap ETF
Anteil0.01%
DFA Dimensional US Core Equity Market ETF
Anteil0%
Global X Russell 2000 ETF
Anteil0%
Avantis US Small Cap Equity ETF
Anteil0%
Proshares Ultra Russell 2000
Anteil0%
ProShares Hedge Replication ETF
Anteil0%
iShares Russell 2000 Growth ETF
Anteil0%
iShares Russell 2000 ETF
Anteil0%
ProShares UltraPro Russell2000
Anteil0%
Global X Russell 2000 Covered Call ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
